

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

## Test

Sample	Group	N	Result	N <sub>rel</sub>
<b>(461) anti-cardiolipin screening</b>				
A	(2) EIA (ELISA)	>>> 15	Positive	94 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 1	Positive	6,3 %
Total per sample: n = 16		Success: 100 %		
B	(2) EIA (ELISA)	>>> 15	Positive	94 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 1	Positive	6,3 %
Total per sample: n = 16		Success: 100 %		
Total success: 100 %				
<b>(463) anti-cardiolipin IgG</b>				
A	(2) EIA (ELISA)	>>> 40	Positive	65 %
	(3) FIA (FEIA, TRACE)	>>> 3	Positive	4,8 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 18	Positive	29 %
	(99) Another measurement principle	>>> 1	Positive	1,6 %
Total per sample: n = 62		Success: 100 %		
B	(2) EIA (ELISA)	>>> 40	Positive	65 %
	(3) FIA (FEIA, TRACE)	>>> 3	Positive	4,8 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 18	Positive	29 %
	(99) Another measurement principle	>>> 1	Positive	1,6 %
Total per sample: n = 62		Success: 100 %		
Total success: 100 %				
<b>(464) anti-cardiolipin IgM</b>				
A	(2) EIA (ELISA)	>>> 39	Negative	62 %
		1	Inconclusive result (borderline)	1,6 %
		1	Positive	1,6 %
	(3) FIA (FEIA, TRACE)	>>> 3	Negative	4,8 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 19	Negative	30 %
Total per sample: n = 63		Success: 97 %		
B	(2) EIA (ELISA)	>>> 41	Negative	65 %
	(3) FIA (FEIA, TRACE)	>>> 3	Negative	4,8 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 19	Negative	30 %
Total per sample: n = 63		Success: 100 %		
Total success: 97 %				
<b>(465) anti-beta2-GP 1 screening</b>				
A	(2) EIA (ELISA)	>>> 13	Positive	93 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 1	Positive	7,1 %
Total per sample: n = 14		Success: 100 %		
B	(2) EIA (ELISA)	>>> 13	Positive	93 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 1	Positive	7,1 %
Total per sample: n = 14		Success: 100 %		
Total success: 100 %				
<b>(467) anti-beta2-GP 1 IgG</b>				
A	(2) EIA (ELISA)	>>> 39	Positive	65 %
	(3) FIA (FEIA, TRACE)	>>> 2	Positive	3,3 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 19	Positive	32 %
Total per sample: n = 60		Success: 100 %		
B	(2) EIA (ELISA)	>>> 39	Positive	65 %
	(3) FIA (FEIA, TRACE)	>>> 2	Positive	3,3 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 19	Positive	32 %
Total per sample: n = 60		Success: 100 %		
Total success: 100 %				
<b>(468) anti-beta2-GP 1 IgM</b>				
A	(2) EIA (ELISA)	>>> 31	Negative	53 %
		1	Inconclusive result (borderline)	1,7 %
		6	Positive	10 %
	(3) FIA (FEIA, TRACE)	>>> 2	Negative	3,4 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 18	Negative	31 %
	(99) Another measurement principle	>>> 1	Negative	1,7 %
Total per sample: n = 59		Success: 88 %		
B	(2) EIA (ELISA)	>>> 38	Negative	64 %
	(3) FIA (FEIA, TRACE)	>>> 2	Negative	3,4 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>> 18	Negative	31 %
	(99) Another measurement principle	>>> 1	Negative	1,7 %
Total per sample: n = 59		Success: 100 %		

### Summary statistics - qualitative results

(Groups: measurement principle)

#### EQA round: APLA1/22 - Antiphospholipid Antibodies

Deadline: 18.03.2022

---

**Test**

Sample	Group	N	Result	N <sub>rel</sub>
--------	-------	---	--------	------------------

---

Total success: 88 %

---

st\_kl

End of report

Printed: 24.03.2022